Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProBioGen Launches Unique Portfolio of Engineered High-Performance Cell Lines

Published: Monday, November 12, 2012
Last Updated: Monday, November 12, 2012
Bookmark and Share
Royalty-free biopharmaceutical CHO production cell lines, individually optimized for enhanced ADCC activity, adjusted galactosylation levels and/or increased production of the target antibodies or proteins.

This elaborate cellular toolbox allows the rapid and targeted creation of antibody and protein molecules with specific pre-defined properties.

The cell's fitness for purpose can either be proven via fee-for-service-based demonstration studies at ProBioGen or by providing the cell lines under research licenses to interested parties. The engineered cell lines are royalty-free and are suitable for clinical and commercial production. All engineered cells are based on ProBioGen's biopharmaceutical CHO platform of DG44 and K1 cell lines and can be freely combined with ProBioGen's stable expression vector system and chemically defined media platform.

Besides applying the described permanent cell modifications to newly created cells lines and molecules, all technologies can also be rapidly introduced into existing protein producer cell lines and even into any clients' own expression platforms.

CHO cells with the following modifications are available:

The GlymaxX® technology boosts antibody ADCC activity by preventing the addition of the sugar "fucose" to the N-linked antibody carbohydrate part in antibody-producing cells. The GlymaxX® technology is based on the introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis. GlymaxX® is universally applicable to different CHO hosts and to any other eukaryotic cell line; it is also simple and potent. It can be applied in a few weeks to any existing antibody producer cell line, or can be included into newly developed cell lines. ProBioGen offers this technology royalty-free to third parties.

The Galactosylation Adjustment Technology is a genetically controlled way to adjust protein galactosylation levels through the additional presence of an enzyme in the producer cells (as opposed to media supplementation to influence galactosylation levels). CHO cells predominantly produce G0 structures (no Galactose molecules).Galactosylation adjustment can increase protein drug galactosylation to almost maximal extent (G2).

The gradual activity of this stably transfected enzyme allows a carefully adjusted or maximized galactosylation of antibodies or proteins. This is desirable e.g. for matching originators galactosylation levels when developing biosimilars, for half-life extension or other reasons.

The Pathway Modulator Technology is highly versatile and readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity. It works through the additional expression of an engineered non-human enzyme in the producer cells. Upon stable transfection, the modulator enzymes' concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs. For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification increased yields between 1.3 and 2.6-fold.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProBioGen to GlymaxX® to Thermo for Allergy Dx Development
The GlymaxX® technology will help in the development of diagnostic tests that deliver even greater clinical precision for the benefit of doctors and allergic patients worldwide.
Wednesday, May 18, 2016
ProBioGen, Eucodis Sign Agreement
Company has signed an exclusive license agreement with Eucodis Bioscience to commercialize C-LiNK, a novel antibody drug conjugation technology.
Wednesday, April 20, 2016
ProBioGen in Biosimilar Deal with Bio Farma Indonesia
Trastuzumab development and transfer for first indonesian on-site production.
Thursday, October 29, 2015
ProBioGen and Tizona Therapeutics Sign Agreement
ADCC-enhancement for innovative cancer therapy, produced via ProBioGen’s accelerated CMC development path.
Tuesday, October 06, 2015
Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials
"Production of the first ever batch of MVA for a clinical trial using a cell line".
Wednesday, June 03, 2015
20 Years ProBioGen
Invests €20 million in mammalian manufacturing expansion.
Wednesday, September 10, 2014
ProBioGen Signs GlymaxX ADCC Enhancement Technology License Deal
A non-exclusive commercial multi-product licensing agreement with Novartis.
Tuesday, June 24, 2014
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
GlymaxX® manufacturing technology improves bispecific antibody activity for solid tumor treatment.
Wednesday, March 05, 2014
ProBioGen and Emergent BioSolutions Partner
ProBioGen announces expansion of commercial licenses with Emergent BioSolutions for AGE1.CR® viral vaccine manufacturing production platform.
Tuesday, December 17, 2013
ProBioGen Upholds Strong Patent Position in Viral Vaccine Manufacturing Field
Company offers licenses and contract research services to human and animal vaccine companies.
Thursday, October 31, 2013
ProBioGen Signs Deal with TOP 10 Pharma Company for Therapeutic Antibody Platform
Another global pharma company has licensed ProBioGen’s GlymaxX® ADCC-enhancement technology.
Wednesday, February 20, 2013
Ceva and ProBioGen Signs Multi-product License Agreement
Ceva takes commercial license for ProBioGen’s AGE1.CR® cell line for viral vaccine production.
Friday, March 16, 2012
ProBioGen and Inhibrx Sign License Deal on GlymaxX® ADCC Technology
GlymaxX® ADCC technology and mammalian cell line development and manufacturing services used to advance therapeutic antibodies.
Friday, October 28, 2011
ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals
ProBioGen to contribute producer cell line development and process engineering for Virdante’s therapeutic protein.
Wednesday, April 28, 2010
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Implementation Science Approaches to Reduce Mother-to-Child HIV Transmission
The NIH study will investigate best practices to ease major disease burden in Sub-Saharan Africa.
Tough New Hydrogel Hybrid Doesn’t Dry Out
Water-based material could be used to make artificial skin, longer-lasting contact lenses.
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
Link Between Canned Food, BPA Exposure Revealed
New Stanford research resolves the debate on the link between canned food and exposure to the hormone-disrupting chemical known as Bisphenol A, or BPA.
Portable Test Rapidly Detects Zika
To better diagnose and track the disease, scientists are now reporting a new $2 test that in the lab can accurately detect low levels of the virus in saliva.
Erasing Unpleasant Memories with a Genetic Switch
Researchers from KU Leuven and the Leibniz Institute for Neurobiology have managed to erase unpleasant memories in mice using a 'genetic switch'.
Unidentified Spectra Detector
New algorithm clusters over 250 million spectra for analysis, such that millions of unidentified peptide sequences can be recognised.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!